Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis | Zendy

Joshua Jones | Zendy; Rina Kimata | Zendy; Osvaldo P. Almeida | Zendy; Graeme J. Hankey | Zendy

Open Access

Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis

Author(s) -

Joshua Jones,

Rina Kimata,

Osvaldo P. Almeida,

Graeme J. Hankey

Publication year - 2021

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.120.032973

Subject(s) - medicine , meta analysis , fluoxetine , stroke (engine) , placebo , randomized controlled trial , relative risk , medline , physical therapy , confidence interval , alternative medicine , serotonin , mechanical engineering , receptor , pathology , political science , law , engineering

Stroke survivors have an increased risk of depression and bone fractures. Selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of fractures in observational studies. Several randomized controlled trials (RCTs) reporting the effect of SSRIs on the risk of fractures in stroke survivors have been published recently but have not been subject to a meta-analysis. We aimed to determine the risk of fractures associated with the use of SSRIs, and the risk of falls, seizures, and recurrent strokes as possible mediators of fractures, in stroke survivors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research